Ali Hamraz
Endocrinology · Walnut Creek
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 4 carriers
- Offices
- 3
- Since medical school
- 27 years
- Graduated 1999
Offices
3 locations · Bass Medical Group · 292 clinicians in this group
Hospitals listed: John Muir Medical Center - Concord Campus · John Muir Medical Center - Walnut Creek Campus. That is not proof they admit you there this week.
Plans that list them
17 plans · 4 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Ali Hamraz’s office at (925) 932-6330 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A161681 · Current
Licensed to practise in California · since 2019 · expires 2027-04-30 · Shahid Beheshti University of Medical Sciences.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Endocrinology, Diabetes and Metabolism
- American Board of Internal Medicine - Internal Medicine
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- John Muir Medical Center - Concord CampusConcord, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of John Muir Health, which runs 3 hospitalsPatients rate it 3 of 5 · 77% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.235, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.675, Oct 2024 – Sep 2025
- John Muir Medical Center - Walnut Creek CampusWalnut Creek, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of John Muir Health, which runs 3 hospitalsPatients rate it 3 of 5 · 77% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — Abdominopelvic accidental puncture or laceration rate: 2.01 (1.17 to 2.85) · 2,206 cases, Jul 2022 – Jun 2024Worse than the national rate — Death rate among surgical inpatients with serious treatable complications: 222.42 (177.82 to 267.02) · 120 cases, Jul 2022 – Jun 2024Worse than the national rate — Pressure ulcer rate: 1.4 (0.91 to 1.9) · 9,764 cases, Jul 2022 – Jun 2024Worse than the national rate — SSI - Colon Surgery: 2.734, Oct 2024 – Sep 2025Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.536, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.341, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.455, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.245, Oct 2024 – Sep 2025
See every measure and the patient survey for John Muir Medical Center - Concord Campus
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 0 better, 7 the same, 0 worse of 7 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.235 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.675 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.11 (0.21 to 2) · 1,612 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.77 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 184.13 (136.65 to 231.6) · 86 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.2 · 175 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.6 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.4 · 172 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8 · 537 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.5 · 434 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 13 · 215 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 3,208 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.32 (0.13 to 0.51) · 7,626 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.04 to 0.41) · 8,660 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.1 (1.29 to 4.91) · 2,723 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.21 (0 to 2.51) · 1,208 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 3 (1.7 to 4.3) · 2,355 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.77 (3.24 to 12.3) · 1,216 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 3.43 (0.43 to 6.43) · 1,253 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.93 (0.47 to 3.4) · 388 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.14 (0.58 to 1.69) · 6,288 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.1 · 263 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.636 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.254 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.904 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.5 · 312 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.1 · 768 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -6.8 · 295 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -3.1 · 648 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 31.1 · 433 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.1 · 504 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.7 (5.1 to 8.8) · 476 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.9 (10.5 to 15.7) · 476 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 250 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 8.8 · 154 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.7 · 186 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.4 (9.9 to 17.9) · 192 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.2) · 546 cases | No different | Jan 2024 – Dec 2024 |
What patients said (521 patients answered, 23% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 72% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 77% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
See every measure and the patient survey for John Muir Medical Center - Walnut Creek Campus
Behind the star rating — Deaths: 3 better, 2 the same, 2 worse of 7 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 3 better, 5 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 2.01 (1.17 to 2.85) · 2,206 cases | Worse | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 222.42 (177.82 to 267.02) · 120 cases | Worse | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.4 (0.91 to 1.9) · 9,764 cases | Worse | Jul 2022 – Jun 2024 |
| SSI - Colon SurgeryInfections | 2.734 | Worse | Oct 2024 – Sep 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.536 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.341 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.455 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.245 | Better | Oct 2024 – Sep 2025 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.14 (0.87 to 1.4) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 131 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 148 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 695 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.5 · 827 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 14.1 · 509 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 4,483 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.35 (0.18 to 0.53) · 11,630 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.05 to 0.39) · 11,793 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.33 (1.69 to 4.96) · 3,268 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.37 (0 to 2.94) · 1,631 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.76 (1.43 to 4.09) · 3,066 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.12 (0.22 to 12.02) · 1,580 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.43 (1.21 to 7.64) · 1,594 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.82 (0.4 to 3.24) · 685 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 615 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 1.88 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.7 · 93 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.9 · 729 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -30.1 · 91 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13 · 736 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 34.8 · 842 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.7 · 818 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.3 (3.3 to 8.4) · 28 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.8 (7.2 to 15.5) · 28 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.9 · 584 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.4 · 139 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.9) · 222 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.5) · 321 cases | No different | Jan 2024 – Dec 2024 |
What patients said (758 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 69% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 77% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$634,200
Medicare paid this office $634,200 for 599 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, romosozumab-aqqg, 1 mg | 33 | $247,581 | None |
| Injection, denosumab, 1 mg | 97 | $193,515 | None |
| Return visit (30+ min) | 403 | $80,457 | $114 |
| Long return visit (40+ min) | 173 | $35,915 | $165 |
| New patient visit (45+ min) | 196 | $27,530 | $140 |
See all 11 services
| Injection, romosozumab-aqqg, 1 mg | 33 | $247,581 | None |
| Injection, denosumab, 1 mg | 97 | $193,515 | None |
| Return visit (30+ min) | 403 | $80,457 | $114 |
| Long return visit (40+ min) | 173 | $35,915 | $165 |
| New patient visit (45+ min) | 196 | $27,530 | $140 |
| Short return visit (20+ min) | 98 | $17,832 | $87 |
| New patient visit (60+ min) | 80 | $15,081 | $189 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | 35 | $6,022 | $163 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 60 | $4,420 | $30 |
| Injection of drug or substance under skin or into muscle | 125 | $4,217 | $14 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 72 | $1,523 | $15 |
Who their Medicare patients are
599 Original Medicare patients in 2024. Average age 75 · Under 65 2% · 85 and older 11% · Women 76% · Also on Medicaid 9% · Health risk score 1.17. At or below the middle of the specialty; the typical endocrinology clinician is at 1.46.
Conditions among them: High blood pressure 70% · Diabetes 34% · Chronic kidney disease 27% · Coronary heart disease 21% · Depression 21% · Cancer 16% · COPD 14% · Atrial fibrillation 14% · Heart failure 11% · Stroke 8% · Dementia 5%.
The office billed $2,093,000, Medicare allowed $810,236 and paid $634,200; for 40,602 services of 12 kinds; $441,097 of it was for drugs given in the office and $193,103 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 599 | 40,602 | 75 | 1.17 | $2,093,000 | $634,200 |
| 2023 | 360 | 43,483 | 75 | 1.07 | $1,896,754 | $530,034 |
| 2022 | 148 | 937 | 75 | 1.08 | $203,546 | $56,073 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Injection, romosozumab-aqqg, 1 mg | 35 | $296,378 | None |
| Injection, denosumab, 1 mg | 62 | $94,005 | None |
| Return visit (30+ min) | 258 | $55,077 | $114 |
| New patient visit (45+ min) | 196 | $28,216 | $144 |
| Short return visit (20+ min) | 87 | $17,573 | $84 |
| Long return visit (40+ min) | 81 | $14,565 | $157 |
| New patient visit (60+ min) | 73 | $13,975 | $191 |
| Injection of drug or substance under skin or into muscle | 93 | $3,633 | $14 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | 18 | $3,094 | $155 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 26 | $1,743 | $28 |
2022: 5 services
| Return visit (30+ min) | 71 | $12,998 | $117 |
| New patient visit (60+ min) | 60 | $11,969 | $199 |
| Long return visit (40+ min) | 44 | $8,913 | $165 |
| New patient visit (45+ min) | 56 | $8,524 | $152 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 11 | $628 | $29 |
Medicaid work
$4,214 in 2024
Medicaid paid $4,214 for 39 billed services this clinician did in 2024, up to 22 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 39 | $4,214 |
| 2024 | 39 | 1 | 22 | $4,214 |
Drugs they prescribed that Part D paid
$1,064,832
Pharmacies billed $1,064,832 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,706) in 2024. At or below the middle of the specialty; the typical endocrinology clinician is at 0%.
859 generic and 784 brand-name prescriptions · $1,064,832 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ozempic | 139 | $226,958 | $1,633 |
| Jardiance | 128 | $194,200 | $1,517 |
| Tymlos | 57 | $147,534 | $2,588 |
| Forteo | 23 | $97,510 | $4,240 |
| Mounjaro | 41 | $56,937 | $1,389 |
See all 31 drugs
| Ozempic | 139 | $226,958 | $1,633 |
| Jardiance | 128 | $194,200 | $1,517 |
| Tymlos | 57 | $147,534 | $2,588 |
| Forteo | 23 | $97,510 | $4,240 |
| Mounjaro | 41 | $56,937 | $1,389 |
| Rybelsus | 32 | $54,085 | $1,690 |
| Trulicity | 30 | $38,896 | $1,297 |
| Farxiga | 19 | $23,536 | $1,239 |
| Tradjenta | 15 | $22,294 | $1,486 |
| Prolia | 11 | $18,904 | $1,719 |
| Fiasp Flextouch | 12 | $9,014 | $751 |
| Humalog Kwikpen U-100 | 17 | $8,034 | $473 |
| Synthroid | 51 | $6,036 | $118 |
| Lantus Solostar | 33 | $5,345 | $162 |
| Novolog Flexpen | 12 | $2,745 | $229 |
| Levothyroxine | 199 | $2,565 | $13 |
| Metformin | 26 | $2,288 | $88 |
| Nano 2nd Gen Pen Needle | 20 | $2,137 | $107 |
| Metformin Hcl Er | 123 | $1,666 | $14 |
| Alendronate | 145 | $1,453 | $10 |
| Pioglitazone | 99 | $1,441 | $15 |
| Ezetimibe | 13 | $1,043 | $80 |
| Glipizide Er | 48 | $793 | $17 |
| Rosuvastatin | 29 | $724 | $25 |
| Ultra-Fine Mini Pen Needle | 11 | $618 | $56 |
| Methimazole | 22 | $568 | $26 |
| Atorvastatin | 49 | $498 | $10 |
| Losartan | 26 | $284 | $11 |
| Glipizide | 11 | $181 | $16 |
| Hydrochlorothiazide | 15 | $105 | $7 |
| Dexamethasone | 14 | $8 | $1 |
Year by year
| 2024 | 1,706 | 309 | 0% (0) | 46% | $1,064,832 |
| 2023 | 841 | 195 | 0% (0) | 41% | $497,531 |
| 2022 | 369 | 101 | 0% (0) | None | $186,684 |
| 2017 | 17 | None | 0% (0) | None | $1,474 |
| 2014 | 24 | None | None | None | $933 |
| 2013 | 45 | 13 | None | None | $1,515 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 24 drugs
| Ozempic | 28 | $61,612 | $2,200 |
| Jardiance | 38 | $60,275 | $1,586 |
| Tymlos | 18 | $49,271 | $2,737 |
| Trulicity | 24 | $48,818 | $2,034 |
| Rybelsus | 24 | $45,749 | $1,906 |
| Mounjaro | 21 | $36,825 | $1,754 |
| Novolog Flexpen | 11 | $14,020 | $1,275 |
| Trijardy Xr | 12 | $12,816 | $1,068 |
| Repatha Sureclick | 11 | $8,823 | $802 |
| Lantus Solostar | 15 | $7,788 | $519 |
| Synthroid | 26 | $3,357 | $129 |
| Levothyroxine | 151 | $3,045 | $20 |
| Ezetimibe | 16 | $2,202 | $138 |
| Metformin Hcl Er | 55 | $1,222 | $22 |
| Rosuvastatin | 26 | $1,190 | $46 |
| Pioglitazone | 48 | $1,045 | $22 |
| Ultra-Fine Short Pen Needle | 12 | $622 | $52 |
| Atorvastatin | 30 | $540 | $18 |
| Alendronate | 47 | $462 | $10 |
| Glipizide | 13 | $334 | $26 |
| Glipizide Er | 14 | $309 | $22 |
| Amlodipine Besylate | 12 | $189 | $16 |
| Metformin | 13 | $145 | $11 |
| Dexamethasone | 21 | $33 | $2 |
2022: 11 drugs
| Jardiance | 31 | $41,274 | $1,331 |
| Trulicity | 14 | $26,362 | $1,883 |
| Synthroid | 14 | $1,576 | $113 |
| Rosuvastatin | 25 | $1,019 | $41 |
| Levothyroxine | 44 | $797 | $18 |
| Pioglitazone | 36 | $688 | $19 |
| Hydrocortisone | 11 | $382 | $35 |
| Metformin Hcl Er | 21 | $245 | $12 |
| Metformin | 15 | $183 | $12 |
| Alendronate | 14 | $181 | $13 |
| Atorvastatin | 12 | $130 | $11 |
Money from drug and device companies
$2,617 in 2025
| 2025 | 23 | 102 | None | $2,617 |
| 2024 | 23 | 95 | None | $2,440 |
| 2023 | 25 | 118 | None | $2,563 |
| 2022 | 22 | 103 | None | $2,403 |
| 2021 | 2 | 3 | None | $128 |
| 2020 | 9 | 13 | None | $246 |
| 2019 | 3 | 7 | None | $497 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Novo Nordisk | Ozempic | $494 | 20 payments
|
| Amgen | Evenity | $262 | 12 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $237 | 7 payments
|
| Radius Health | Tymlos | $231 | 10 payments
|
| Dexcom | Dexcom G7 Gss (161) | $183 | 2 payments
|
| Lilly USA | Mounjaro | $151 | 8 payments
|
See all 101 published payments
| Radius Health | Meals · 2025-12-15 | Tymlos | $6 |
| Radius Health | Meals · 2025-12-15 | Tymlos | $16 |
| Dexcom | Meals · 2025-12-11 | Dexcom G6 Transmitter | $37 |
| Amgen | Meals · 2025-12-10 | Tepezza | $7 |
| Xeris Pharmaceuticals | Meals · 2025-12-10 | Recorlev | $25 |
| Recordati Rare Diseases Inc. | Meals · 2025-12-08 | Isturisa | $22 |
| Novo Nordisk | Meals · 2025-12-06 | Ozempic | $15 |
| Amgen | Meals · 2025-12-04 | Tepezza | $29 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-12-03 | Jardiance | $21 |
| Amgen | Meals · 2025-11-14 | Tepezza | $10 |
| Novo Nordisk | Meals · 2025-11-13 | Rybelsus | $9 |
| Amgen | Meals · 2025-11-11 | Evenity | $27 |
| Sequel Med Tech | Meals · 2025-10-27 | Twiist | $23 |
| Radius Health | Meals · 2025-10-24 | Tymlos | $24 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-10-21 | Jardiance | $19 |
| Amgen | Meals · 2025-10-21 | Evenity | $6 |
| Novo Nordisk | Meals · 2025-10-20 | Rybelsus | $6 |
| Antares Pharma | Meals · 2025-10-20 | Xyosted | $21 |
| Novo Nordisk | Meals · 2025-10-15 | Rybelsus | $24 |
| Lilly USA | Meals · 2025-10-13 | Mounjaro | $26 |
| Novo Nordisk | Meals · 2025-10-07 | Rybelsus | $20 |
| Lilly USA | Meals · 2025-10-03 | Mounjaro | $6 |
| Novo Nordisk | Meals · 2025-10-01 | None | $125 |
| Acella Pharmaceuticals | Meals · 2025-09-22 | NP Thyroid 60 | $17 |
| Xeris Pharmaceuticals | Meals · 2025-09-17 | Gvoke Hypopen | $24 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-09-16 | Kerendia | $24 |
| Alexion Pharmaceuticals | Meals · 2025-09-12 | Strensiq | $32 |
| Madrigal Pharmaceuticals | Meals · 2025-09-12 | Rezdiffra | $32 |
| Lilly USA | Meals · 2025-09-09 | Mounjaro | $21 |
| Amgen | Meals · 2025-09-08 | Evenity | $28 |
| Radius Health | Meals · 2025-08-28 | Tymlos | $32 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-08-27 | Jardiance | $22 |
| Lilly USA | Meals · 2025-08-26 | Mounjaro | $27 |
| Novo Nordisk | Meals · 2025-08-21 | Rybelsus | $24 |
| Amgen | Meals · 2025-08-21 | Tepezza | $24 |
| Novo Nordisk | Meals · 2025-08-19 | Wegovy | $23 |
| Sequel Med Tech | Meals · 2025-08-18 | Twiist | $15 |
| Novo Nordisk | Meals · 2025-08-14 | Rybelsus | $6 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-08-13 | Jardiance | $119 |
| Sanofi-Aventis U.S. | Meals · 2025-08-13 | Tzield | $29 |
| Madrigal Pharmaceuticals | Meals · 2025-08-06 | Rezdiffra | $40 |
| Antares Pharma | Meals · 2025-08-05 | Xyosted | $23 |
| Radius Health | Meals · 2025-07-30 | Tymlos | $30 |
| Ascendis Pharma Endocrinology | Meals · 2025-07-25 | Yorvipath | $27 |
| Amgen | Meals · 2025-07-23 | Evenity | $32 |
| Sanofi-Aventis U.S. | Meals · 2025-07-17 | Tzield | $21 |
| Novo Nordisk | Meals · 2025-07-08 | Rybelsus | $18 |
| Alexion Pharmaceuticals | Meals · 2025-06-24 | Strensiq | $32 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-06-18 | Kerendia | $24 |
| Dexcom | Meals · 2025-06-14 | Dexcom G7 Gss (161) | $146 |
| Madrigal Pharmaceuticals | Meals · 2025-06-12 | Rezdiffra | $42 |
| Medtronic | Meals · 2025-06-11 | Minimed 780g | $24 |
| Amgen | Meals · 2025-06-10 | Evenity | $11 |
| Abbvie | Meals · 2025-05-30 | Synthroid | $24 |
| Tandem Diabetes Care | Meals · 2025-05-28 | T:Slim X2 Insulin Pump With Control-Iq | $22 |
| Lilly USA | Meals · 2025-05-27 | Mounjaro | $8 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-05-27 | Jardiance | $22 |
| Amgen | Meals · 2025-05-22 | Tepezza | $31 |
| Recordati Rare Diseases Inc. | Meals · 2025-05-21 | Isturisa | $28 |
| Alexion Pharmaceuticals | Meals · 2025-05-21 | Strensiq | $29 |
| Lilly USA | Meals · 2025-05-19 | Mounjaro | $24 |
| Sanofi-Aventis U.S. | Meals · 2025-05-15 | Tzield | $28 |
| Radius Health | Meals · 2025-05-14 | Tymlos | $33 |
| Kyowa Kirin | Meals · 2025-05-13 | Crysvita | $30 |
| Novo Nordisk | Meals · 2025-05-12 | Rybelsus | $8 |
| Antares Pharma | Meals · 2025-05-12 | Xyosted | $24 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-05-06 | Kerendia | $24 |
| Mannkind | Meals · 2025-05-05 | Afrezza | $15 |
| Amgen | Meals · 2025-04-29 | Evenity | $30 |
| Insulet | Meals · 2025-04-24 | Omnipod | $18 |
| Novo Nordisk | Meals · 2025-04-15 | Ozempic | $20 |
| Novo Nordisk | Meals · 2025-04-15 | Ozempic | $11 |
| Radius Health | Meals · 2025-04-10 | Tymlos | $28 |
| Novo Nordisk | Meals · 2025-04-03 | Wegovy | $24 |
| Mannkind | Meals · 2025-04-03 | Afrezza | $20 |
| Novo Nordisk | Meals · 2025-04-02 | Ozempic | $8 |
| Radius Health | Meals · 2025-03-27 | Tymlos | $5 |
| Radius Health | Meals · 2025-03-27 | Tymlos | $28 |
| Lilly USA | Meals · 2025-03-25 | Mounjaro | $24 |
| Novo Nordisk | Meals · 2025-03-25 | Ozempic | $99 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-03-24 | Jardiance | $17 |
| Sanofi-Aventis U.S. | Meals · 2025-03-20 | Tzield | $17 |
| Abbvie | Meals · 2025-03-19 | Synthroid | $27 |
| Almatica Pharma | Meals · 2025-03-19 | Teriparatide | $25 |
| Xeris Pharmaceuticals | Meals · 2025-03-13 | Gvoke Hypopen | $21 |
| Novo Nordisk | Meals · 2025-03-04 | Ozempic | $27 |
| Novo Nordisk | Meals · 2025-02-25 | Ozempic | $21 |
| Antares Pharma | Meals · 2025-02-25 | Xyosted | $24 |
| Sanofi-Aventis U.S. | Meals · 2025-02-11 | Tzield | $25 |
| Ascendis Pharma Endocrinology | Meals · 2025-02-11 | Yorvipath | $30 |
| Novo Nordisk | Meals · 2025-02-06 | Ozempic | $2 |
| Alexion Pharmaceuticals | Meals · 2025-02-06 | Strensiq | $29 |
| Amgen | Meals · 2025-02-04 | Evenity | $27 |
| Ascendis Pharma Endocrinology | Meals · 2025-02-01 | Yorvipath | $18 |
| Radius Health | Meals · 2025-01-30 | Tymlos | $29 |
| Lilly USA | Meals · 2025-01-28 | Mounjaro | $16 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-01-23 | Kerendia | $28 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-01-21 | Jardiance | $17 |
| Medtronic | Meals · 2025-01-16 | Minimed 780g | $25 |
| Novo Nordisk | Meals · 2025-01-15 | Rybelsus | $5 |
| Abbvie | Meals · 2025-01-10 | Synthroid | $29 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $2,440
| Amgen | Evenity | $442 | 13 payments
|
| Beta Bionics | Ilet Bionic Pancreas | $268 | 3 payments
|
| Radius Health | Tymlos | $261 | 8 payments
|
| Lilly USA | Mounjaro | $213 | 10 payments
|
| Novo Nordisk | Ozempic | $172 | 13 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $164 | 7 payments
|
| Antares Pharma | Xyosted | $136 | 6 payments
|
| Verity Pharmaceuticals | Tlando | $132 | 5 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $122 | 6 payments
|
| Sanofi-Aventis U.S. | Tzield | $86 | 4 payments
|
| Recordati Rare Diseases Inc. | Signifor Lar | $81 | 3 payments
|
| Ascensia Diabetes Care Us | Eversense 365 Sensor Kit (Retail) | $45 | 2 payments
|
| Mannkind | Afrezza | $40 | 2 payments
|
| Xeris Pharmaceuticals | Gvoke Hypopen | $38 | 2 payments
|
| Dexcom | Dexcom G6 Transmitter | $36 | 1 payment
|
| Medtronic | Minimed 780g | $29 | 1 payment
|
| Alexion Pharmaceuticals | Strensiq | $28 | 1 payment
|
| Kyowa Kirin | Crysvita | $27 | 1 payment
|
| Corcept Therapeutics | Korlym | $27 | 1 payment
|
| Almatica Pharma | Teriparatide | $25 | 1 payment
|
| Abbvie | Ubrelvy | $24 | 1 payment
|
| Tandem Diabetes Care | T:Slim X2 Insulin Pump With Control-Iq | $23 | 1 payment
|
| RGH Enterprises | None | $22 | 1 payment
|
2023: $2,563
| Bayer Healthcare Pharmaceuticals | Kerendia | $351 | 14 payments
|
| Amgen | Evenity | $329 | 11 payments
|
| Novo Nordisk | Ozempic | $325 | 24 payments
|
| Lilly USA | Trulicity | $217 | 10 payments
|
| Corcept Therapeutics | Korlym | $187 | 8 payments
|
| Radius Health | Tymlos | $141 | 7 payments
|
| Supernus Pharmaceuticals | Xyosted | $124 | 5 payments
|
| MannKind | Afrezza | $119 | 5 payments
|
| IBSA Pharma | Tirosint | $116 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $94 | 5 payments
|
| Antares Pharma | Nocdurna | $71 | 3 payments
|
| Abbott Laboratories | Freestyle Libre 3 | $64 | 4 payments
|
| Xeris Pharmaceuticals | Gvoke Hypopen | $56 | 3 payments
|
| Kyowa Kirin | Crysvita | $53 | 2 payments
|
| Sanofi-Aventis U.S. | Toujeo | $45 | 3 payments
|
| Tandem Diabetes Care | T:Slim X2 Insulin Pump With Control-Iq | $36 | 2 payments
|
| Insulet | Omnipod | $34 | 2 payments
|
| Recordati Rare Diseases Inc. | Signifor Lar | $33 | 1 payment
|
| Currax Pharmaceuticals | Contrave | $29 | 2 payments
|
| Abbvie | Synthroid | $27 | 1 payment
|
| Ascendis Pharma | Skytrofa | $27 | 1 payment
|
| Dexcom | Dexcom G6 Transmitter | $26 | 1 payment
|
| Amryt Pharma Holdings | Mycapssa | $24 | 1 payment
|
| RGH Enterprises | None | $19 | 1 payment
|
| Horizon Therapeutics plc | Tepezza | $15 | 1 payment
|
2022: $2,403
| Bayer HealthCare Pharmaceuticals | Kerendia | $363 | 17 payments
|
| Novo Nordisk | Ozempic | $330 | 16 payments
|
| Corcept Therapeutics | Korlym | $245 | 7 payments
|
| Amgen | Evenity | $225 | 8 payments
|
| Radius Health | Tymlos | $193 | 9 payments
|
| Mannkind | Afrezza | $171 | 8 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $170 | 6 payments
|
| Lilly USA | Mounjaro | $127 | 5 payments
|
| Medtronic | Minimed 770g | $90 | 3 payments
|
| Abbvie | Synthroid | $77 | 4 payments
|
| Horizon Therapeutics plc | Tepezza | $71 | 3 payments
|
| Abbott Laboratories | Freestyle Libre 2 | $51 | 3 payments
|
| Sanofi-Aventis U.S. | Toujeo | $45 | 2 payments
|
| Antares Pharma | Nocdurna | $39 | 2 payments
|
| Insulet | Omnipod | $38 | 2 payments
|
| Tandem Diabetes Care | T:Slim X2 Insulin Pump With Control-Iq | $32 | 2 payments
|
| Nevro | Omnia | $29 | 1 payment
|
| Bigfoot Biomedical | Unity Diabetes Management System | $28 | 1 payment
|
| Recordati Rare Diseases Inc. | Signifor Lar | $21 | 1 payment
|
| EUSA Pharma (US) | Sylvant | $21 | 1 payment
|
| CeQur | Cequr Simplicity | $20 | 1 payment
|
| Dexcom | Dexcom G6 Transmitter | $17 | 1 payment
|
2021: $128
| Novo Nordisk | Ozempic | $115 | 2 payments
|
| MannKind | Afrezza | $14 | 1 payment
|
2020: $246
| Novo Nordisk | Ozempic | $45 | 3 payments
|
| LifeScan | Ot Reveal Mobile App | $41 | 2 payments
|
| Becton Dickinson and | Bd Nano | $39 | 1 payment
|
| Janssen Pharmaceuticals | Invokana | $30 | 2 payments
|
| Corcept Therapeutics | Korlym | $22 | 1 payment
|
| Amgen | Repatha | $21 | 1 payment
|
| Amarin Pharma | Vascepa | $21 | 1 payment
|
| Companion Medical | Inpen | $18 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $11 | 1 payment
|
2019: $497
| Novo Nordisk | Ozempic | $256 | 5 payments
|
| Corcept Therapeutics | Korlym | $127 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | None | $114 | 1 payment
|
Professional record
- NPI
- 1083901961
- Licence
- CA A161681, NV LL2943California A161681: Current · expires 2027-04-30
- Group
- Bass Medical Group
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207RE0101X (207RE0101X); Internal medicine (207R00000X)
- Mailing address
- 2637 Shadelands Dr, Walnut Creek, CA, 94598
- NPI first listed
- 2011-06-29
- NPI last updated
- 2025-01-07
- NPI record certified
- 2025-01-07
This is when the NPI record was last certified, not a medical board exam.